Skip to main content

Elisa Marín Ordovás

Institutions of which they are part

Predoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Elisa Marín Ordovás

Institutions of which they are part

Predoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Búsqueda de compuestos que bloquean la acción de la chitinase 3-like 1 sobre las neuronas como tratamiento para los pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Búsqueda de compuestos que bloquean la acción de la chitinase 3-like 1 sobre las neuronas como tratamiento para los pacientes c, Andreu Vilaseca Jolonch, Elisa Marín Ordovás, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 233750
Reference: PI24/01088
Duration: 01/01/2025 - 31/12/2027

Mecanismos subyacentes del daño axonal y discapacidad en enfermedad asociada a anticuerpos anti-MOG: Estudio MOGAXON

IP: Alvaro Cobo Calvo
Collaborators: Cristina Auger Acosta, Miguel Angel Robles Sanchez, Elisa Marín Ordovás, Mireia Castillo Juarez, Luca Bollo
Funding agency: Instituto de Salud Carlos III
Funding: 201875
Reference: PI24/00859
Duration: 01/01/2025 - 31/12/2027

Modelos humanizados basados en células madre pluripotentes inducidas para estudiar la patología oligodendroglial y estrategias de remielinización en pacientes con esclerosis múltiple

IP: Andres Miguez Gonzalez
Collaborators: Gloria López Comellas, Elisa Marín Ordovás, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 140000
Reference: PI24/01117
Duration: 01/01/2025 - 31/12/2027

Beca VHIR PhD

IP: Manuel Comabella Lopez
Collaborators: Laia Perez Lasarte, Elisa Marín Ordovás, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 69188.74
Reference: VPHD/ELISA_M
Duration: 01/04/2023 - 31/03/2026

Related news

A Vall d’Hebron study, carried out at Cemcat, shows that the risk of inflammatory activity increases after discontinuing treatment, but is considerably reduced in people over 60 years of age.

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.

Related professionals

David Clofent Alarcón

David Clofent Alarcón

Main researcher
Pneumology
Read more
Sara Ceballos Aballe

Sara Ceballos Aballe

Research technician
Rheumatology
Read more
Carmen Tur Gomez

Carmen Tur Gomez

Main researcher
Clinical Neuroimmunology
Read more
Lya Leal Mijares

Lya Leal Mijares

Gestió i Administració
Commercial and Academic Clinical Research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.